CALL/VERTEX PHARMACEUTICALS/600/0.1/20.06.25 | Market Closed - BOERSE MUENCHEN 11:57:02 07/06/2024 pm IST | ||
| 2.38 EUR | +4.85% |
|
| Current month | +68.79% | ||
| 1 month | +221.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 2.38 | +4.85% |
| 06/24/06 | 2.27 | -1.73% |
| 05/24/05 | 2.31 | +10.53% |
| 04/24/04 | 2.09 | +15.47% |
| 03/24/03 | 1.81 | +28.37% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 11:57 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG2S5R |
| ISIN | DE000GG2S5R9 |
| Date issued | 18/01/2024 |
| Strike | 600 $ |
| Maturity | 20/06/2025 (377 Days) |
| Parity | 10 : 1 |
| Emission price | 1.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.39 € |
|---|---|
| Lowest since issue | 0.623 € |
| Spread | 0.2 € |
| Spread % | 8.23% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant
